SOURCE: StockCall

StockCall

December 13, 2010 08:19 ET

Equity Research on StemCells Inc. and Life Technologies Corporation - Biotechnology Equipment Makers Set for Profits

JOHANNESBURG, SOUTH AFRICA--(Marketwire - December 13, 2010) - www.stockcall.com/ offers investors comprehensive research on the biotechnology industry and has completed analytical research on StemCells Inc. (NASDAQ: STEM) and Life Technologies Corporation (NASDAQ: LIFE). Register with us today at www.stockcall.com/ to have free access to these researches. 

While healthcare has proven to be one of the more stable stocks during the recession, biotechnology companies have traditionally been rather volatile. With potential profitability often hinging on a company's research and development or FDA approvals, it can be difficult to predict winners or losers. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the biotechnology industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the biotechnology industry can have easy and free access to our analyst research and opinions on StemCells Inc. and Life Technologies Corporation; investors and shareholders of these companies can simply register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html

Since the Obama administration has taken office, the healthcare sector has reported increasing satisfaction with the generally difficult to deal with FDA. While the FDA has been somewhat stingy on its approvals lately, it has decided to provide increased patent protection to biosimilar generics in the field of gene-based medicines. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

One area within the Biotechnology sector that should be relatively strong is equipment makers and suppliers. While the Obama administration's recent approval of $1 billion in research and development tax credits for the sector has generally been regarded as a drop in the bucket due to its dilution over a large amount of companies, it will nonetheless provide funding to generally cash strapped research labs, allowing them to upgrade and restock their equipment and supplies.

With weak pipelines, many companies and universities are scrambling to develop new drugs with the onset of the next few years patent cliffs. This combined with enormous growth in emerging markets should help fuel this segment of the Biotechnology sector during the coming years.

Looking at the results from some of the players in this sphere for the third quarter 2010, StemCells Inc. which released its readings in the first week of November saw a loss of over $5.5 million. StemCells Inc. research report is accessible for free by registering today at www.stockcall.com/STEM131210.pdf

Conversely, Life Technologies Corporation posted upbeat results for the quarter with net income coming at $105.5 million backed by an increasing demand for its tools & equipment which are used in biological research. The company also saw revenue for Q3 2010 grow by 8% to $869 million. Life Technologies Corporation research report is available for free by signing up now at www.stockcall.com/LIFE131210.pdf

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information